More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma

. 2023 Mar 01 ; 41 (7) : 1383-1392. [epub] 20221031

Jazyk angličtina Země Spojené státy americké Médium print-electronic

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid36315921

Grantová podpora
C355/A26819 Cancer Research UK - United Kingdom

PURPOSE: Primary plasma cell leukemia (PCL) is the most aggressive monoclonal gammopathy. It was formerly characterized by ≥ 20% circulating plasma cells (CTCs) until 2021, when this threshold was decreased to ≥ 5%. We hypothesized that primary PCL is not a separate clinical entity, but rather that it represents ultra-high-risk multiple myeloma (MM) characterized by elevated CTC levels. METHODS: We assessed the levels of CTCs by multiparameter flow cytometry in 395 patients with newly diagnosed transplant-ineligible MM to establish a cutoff for CTCs that identifies the patients with ultra-high-risk PCL-like MM. We tested the cutoff on 185 transplant-eligible patients with MM and further validated on an independent cohort of 280 transplant-ineligible patients treated in the GEM-CLARIDEX trial. The largest published real-world cohort of patients with primary PCL was used for comparison of survival. Finally, we challenged the current 5% threshold for primary PCL diagnosis. RESULTS: Newly diagnosed transplant-ineligible patients with MM with 2%-20% CTCs had significantly shorter progression-free survival (3.1 v 15.6 months; P < .001) and overall survival (14.6 v 33.6 months; P = .023) than patients with < 2%. The 2% cutoff proved to be applicable also in transplant-eligible patients with MM and was successfully validated on an independent cohort of patients from the GEM-CLARIDEX trial. Most importantly, patients with 2%-20% CTCs had comparable dismal outcomes with primary PCL. Moreover, after revealing a low mean difference between flow cytometric and morphologic evaluation of CTCs, we showed that patients with 2%-5% CTCs have similar outcomes as those with 5%-20% CTCs. CONCLUSION: Our study uncovers that ≥ 2% CTCs is a biomarker of hidden primary PCL and supports the assessment of CTCs by flow cytometry during the diagnostic workup of MM.

Zobrazit více v PubMed

van de Donk NWCJ, Pawlyn C, Yong KL: Multiple myeloma. Lancet 397:410-427, 2021 PubMed

Rodriguez-Otero P, Paiva B, San-Miguel JF: Roadmap to cure multiple myeloma. Cancer Treat Rev 100:102284, 2021 PubMed

Garcés J-J, Simicek M, Vicari M, et al. : Transcriptional profiling of circulating tumor cells in multiple myeloma: A new model to understand disease dissemination. Leukemia 34:589-603, 2020 PubMed

Garcés J-J, Cedena M-T, Puig N, et al. : Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma. J Clin Oncol 40:3151-3161, 2022 PubMed

Sanoja-Flores L, Paiva B, Flores-Montero JA, et al. : Next generation flow (NGF): A high sensitive technique to detect circulating peripheral blood (PB) clonal plasma cells (cPC) in patients with newly diagnosed of plasma cell neoplasms (PCN). Blood 126:4180, 2015

Sanoja-Flores L, Flores-Montero J, Garcés JJ, et al. : Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J 8:117, 2018 PubMed PMC

Bertamini L, Oliva S, Rota-Scalabrini D, et al. : High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma. J Clin Oncol 40:3120-3131, 2022 PubMed

Chakraborty R, Lentzsch S: Circulating tumor cell burden as a component of staging in multiple myeloma: Ready for prime time? J Clin Oncol 40:3099-3102, 2022 PubMed

Kyle RA, Maldonado JE, Bayrd ED: Plasma cell leukemia. Report on 17 cases. Arch Intern Med 133:813-818, 1974 PubMed

Jelinek T, Kryukov F, Rihova L, et al. : Plasma cell leukemia: From biology to treatment. Eur J Haematol 95:16-26, 2015 PubMed

Fernández de Larrea C, Kyle R, Rosiñol L, et al. : Primary plasma cell leukemia: Consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J 11:192, 2021 PubMed PMC

Registry of Monoclonal Gammopathies. https://rmg.healthregistry.org/

Jurczyszyn A, Radocha J, Davila J, et al. : Prognostic indicators in primary plasma cell leukaemia: A multicentre retrospective study of 117 patients. Br J Haematol 180:831-839, 2018 PubMed

Puig N, Hernández MT, Rosiñol L, et al. : Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: A randomized trial. Blood Cancer J 11:101, 2021 PubMed PMC

Flores-Montero J, Sanoja-Flores L, Paiva B, et al. : Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 31:2094-2103, 2017 PubMed PMC

Ravi P, Kumar SK, Roeker L, et al. : Revised diagnostic criteria for plasma cell leukemia: Results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood Cancer J 8:116, 2018 PubMed PMC

Granell M, Calvo X, Garcia-Guiñón A, et al. : Prognostic impact of circulating plasma cells in patients with multiple myeloma: Implications for plasma cell leukaemia definition. Haematologica 102:1099-1104, 2017 PubMed PMC

Gonsalves WI, Rajkumar SV, Go RS, et al. : Trends in survival of patients with primary plasma cell leukemia: A population-based analysis. Blood 124:907-912, 2014 PubMed PMC

Nahi H, Genell A, Wålinder G, et al. : Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register. Eur J Haematol 99:216-222, 2017 PubMed

Hofste Op Bruinink D, Kuiper R, van Duin M, et al. : Identification of high-risk multiple myeloma with a plasma cell leukemia-like transcriptomic profile. J Clin Oncol 40:3132-3150, 2022 PubMed PMC

Musto P, Simeon V, Martorelli MC, et al. : Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia 28:222-225, 2014 PubMed

Bland JM, Altman DG: Measuring agreement in method comparison studies. Stat Methods Med Res 8:135-160, 1999 PubMed

Greipp PR, San Miguel J, Durie BGM, et al. : International staging system for multiple myeloma. J Clin Oncol 23:3412-3420, 2005 PubMed

Palumbo A, Avet-Loiseau H, Oliva S, et al. : Revised International staging system for multiple myeloma: A Report from International Myeloma Working Group. J Clin Oncol 33:2863-2869, 2015 PubMed PMC

D’Agostino M, Cairns DA, Lahuerta JJ, et al. : Second Revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: A European Myeloma Network (EMN) report within the HARMONY Project. J Clin Oncol 40:3406-3418, 2022 PubMed

Gonsalves WI, Jevremovic D, Nandakumar B, et al. : Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. Am J Hematol 95:310-315, 2020 PubMed PMC

Galieni P, Travaglini F, Vagnoni D, et al. : The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma. Br J Haematol 193:542-550, 2021 PubMed

Cheng Q, Cai L, Zhang Y, et al. : Circulating plasma cells as a biomarker to predict newly diagnosed multiple myeloma prognosis: Developing nomogram prognostic models. Front Oncol 11:639528, 2021 PubMed PMC

Gonsalves WI, Buadi FK, Kumar SK: Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14). Eur J Haematol 100:215-217, 2018 PubMed

Jelinek T, Mihalyova J, Kascak M, et al. : Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14). Am J Hematol 94:E35-E37, 2019 PubMed

Jelinek T, Sevcikova T, Zihala D, et al. : Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia 36:288-291, 2022 PubMed

Moreau P, Garfall AL, van de Donk NWCJ, et al. : Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 387:495-505, 2022 PubMed PMC

Martin T, Usmani SZ, Berdeja JG, et al. : Ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 41:1265-1274, 2023 PubMed PMC

Moreau P, Masszi T, Grzasko N, et al. : Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374:1621-1634, 2016 PubMed

Dimopoulos MA, Oriol A, Nahi H, et al. : Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375:1319-1331, 2016 PubMed

Schjesvold FH, Dimopoulos M-A, Delimpasi S, et al. : Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): A randomised, head-to-head, open-label, phase 3 study. Lancet Haematol 9:e98-e110, 2022 PubMed

Gay F, Musto P, Rota-Scalabrini D, et al. : Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): A randomised, open-label, phase 2 trial. Lancet Oncol 22:1705-1720, 2021 PubMed

Rosiñol L, Oriol A, Rios R, et al. : Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood 134:1337-1345, 2019 PubMed PMC

Bezdekova R, Jelinek T, Kralova R, et al. : Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia. Br J Haematol 195:95-107, 2021 PubMed PMC

Jelinek T, Bezdekova R, Zatopkova M, et al. : Current applications of multiparameter flow cytometry in plasma cell disorders. Blood Cancer J 7:e617, 2017 PubMed PMC

Paiva B, Puig N, Cedena M-T, et al. : Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol 38:784-792, 2020 PubMed

Fernández de Larrea C, Kyle RA, Durie BGM, et al. : Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 27:780-791, 2013 PubMed PMC

An G, Qin X, Acharya C, et al. : Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients. Ann Hematol 94:257-264, 2015 PubMed

Katodritou E, Terpos E, Delimpasi S, et al. : Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: A multicenter national study by the Greek Myeloma Study Group. Blood Cancer J 8:31, 2018 PubMed PMC

Nandakumar B, Kumar SK, Dispenzieri A, et al. : Clinical characteristics and outcomes of patients with primary plasma cell leukemia in the era of novel agent therapy. Mayo Clin Proc 96:677-687, 2021 PubMed PMC

Zobrazit více v PubMed

ClinicalTrials.gov
NCT02575144

Najít záznam

Citační ukazatele

Možnosti archivace